Search

Search results

97 results found

What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower Respiratory Tract Infections, including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-world Setting in India?

Talwar, Deepak, Agam Vora, Chandrakant Tarke, Asmita Mehta, Naveed Nazir Shah, and Sonia Dalal. 2025. “What Makes Cefpodoxime an Empiric Drug of Choice to Treat Lower Respiratory Tract Infections, Including Acute Exacerbation of Chronic Obstructive Pulmonary Disease, in the Real-World Setting in India?”. The Journal of the Association of Physicians of India 73 (10): e55-e59.

Review of Safety and Efficacy of Polmacoxib: A Novel Dual Inhibitor of Cyclo-oxygenase 2 and Carbonic Anhydrase in Osteoarthritis and Acute Painful Conditions.

Gunjal, Vijaya Sandeep, Roshan Rambhau Pawar, and Akhilesh Dayanand Sharma. 2025. “Review of Safety and Efficacy of Polmacoxib: A Novel Dual Inhibitor of Cyclo-Oxygenase 2 and Carbonic Anhydrase in Osteoarthritis and Acute Painful Conditions.”. The Journal of the Association of Physicians of India 73 (10): 88-92.